Clinical trial · no report yet · Phase 2

SWOG S1702 trial: what clinicians have said so far

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808 ↗
Completed
SWOG Cancer Research Network
Focused size, estimated: 1–150 verified statements once built

We haven't built an HCP commentary report on SWOG S1702 (isatuximab in relapsed and/or refractory AL amyloidosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on SWOG S1702 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
8 posts on X, typically up to 35 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Phase: Phase 2
Status: Completed
Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Isatuximab; Laboratory Biomarker Analysis
Arms: Treatment (isatuximab) · Experimental
Enrollment: 43
Primary outcomes: Assess Efficacy by Confirmed Overall Hematologic Response
Sponsor: SWOG Cancer Research Network with National Cancer Institute (NCI)
Start: Jun 6, 2018
Primary completion: Aug 30, 2023
Results posted: Yes
Registry record: NCT03499808 · updated Sep 9, 2025

Publications

linked from the registry

Parker TL, Rosenthal A, Sanchorawala V, Landau HJ, Campagnaro EL, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott EC, Hoering A, Durie BGM, Orlowski RZ. Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702). Blood. 2025 Nov 20;146(21):2507-2516. doi: 10.1182/blood.2024027962. PubMed 40925099

Get this report

Focused

Report, built on orderBuilt within 24 hours of confirming your order: $750

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md